# A Multicenter, Randomized, Double-Blind Parallel-Group, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg Once Daily to Placebo qd for the Resolution of Upper Abdominal Pain in Patients With Symptomatic Gastroesophageal Reflux Disease (sGERD)

> **NCT00626535** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 500 (estimated)

## Conditions studied

- Symptomatic Gastroesophageal Reflux Disease (sGERD)

## Interventions

- **DRUG:** Esomeprazole
- **DRUG:** Matching placebo

## Key facts

- **NCT ID:** NCT00626535
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-03
- **Primary completion:** 2004-02
- **Final completion:** 2004-02
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2009-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00626535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00626535, "A Multicenter, Randomized, Double-Blind Parallel-Group, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg Once Daily to Placebo qd for the Resolution of Upper Abdominal Pain in Patients With Symptomatic Gastroesophageal Reflux Disease (sGERD)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00626535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*